FINWIRES · TerminalLIVE
FINWIRES

South Korea's Industrial Output, Retail Sales Weaken in April as Iran War Disrupts Supply Chains

By
South Korea's Industrial Output, Retail Sales Weaken in April as Iran War Disrupts Supply Chains

South Korea's industrial output and retail sales weakened in April amid global supply disruptions and elevated fuel costs stemming from the US-Iran conflict.

Industrial production slipped 0.6% from the previous month, according to data released Friday by the Ministry of Data and Statistics.

Mining and manufacturing output slid 0.7%, while construction fell 1.4%. The service sector also declined 1%, with finance and insurance dropping 7.7%. The information and telecommunications segment bucked the trend, rising 4.3%.

Within manufacturing, semiconductor output rose 3.1%. Automobile production, however, fell 10%, and petroleum output plunged 19.4%, the steepest drop in decades, reflecting supply disruptions tied to the US-Iran conflict.

The finance ministry, in a separate statement, attributed part of the decline to production disruptions caused by a fire at an auto parts supplier.

On a year-over-year basis, industrial output rose 2.4%, softer than the 3.7% increase in March.

Despite the weak April figures, the ministry expects industrial activity to rebound in May, citing a recovery in consumer sentiment and a business sentiment index that reached its highest level in 43 months.

"It appears the figures were affected both by a base effect following gains in February and March and by the Middle East war," Lee Doo-won, a senior official at the data ministry, was quoted by The Korea Herald as saying.

Meanwhile, retail sales contracted 3.6% from the prior month but rose 1.6% year on year. Sales of semi-durable goods were flat, while durable goods, including telecommunications equipment and computers, slumped 11.1%. Non-durable goods such as fuel edged down 1.1%.

The government said it will continue fuel price relief measures and other steps to minimize the economic fallout from the conflict.

The outlook for this year's economy was also revised upward, with the Bank of Korea raising its growth forecast to 2.6% from 2% and the Korea Development Institute lifting its projection to 2.5% from 1.9%.

The BoK held its benchmark interest rate at 2.5% amid ongoing uncertainties surrounding the war, but signaled a more hawkish stance later in the year.

Related Articles

Philippine Trade Deficit Widens 49.8% in April as Export Growth Slows
US Markets

Philippine Trade Deficit Widens 49.8% in April as Export Growth Slows

The Philippines' trade deficit widened sharply in April as import growth significantly outpaced exports.The trade gap ballooned 49.8% year over year to $5.97 billion, marking a steep acceleration from the 11.4% deficit growth recorded in Marchm according to Friday data from the Philippine Statistics Authority.Imports surged 22.4% from a year earlier to $13.2 billion, up from the 17% growth seen the previous month. Meanwhile, exports rose 6.3% to $7.21 billion, a notable slowdown from March's 20.8% jump.Electronic products posted the highest annual increase among imports, climbing by $1.85 billion. Despite global supply chain disruptions triggered by the Middle East conflict, domestic demand for gadgets, such as smartphones, computers, and cameras-remained robust.A December 2025 report from Statista noted that the Philippines' growing middle class continues to drive consumption of these goods, with the broader electronics sector forecast to expand steadily over the next five years.This was followed by mineral fuels, which increased by $1.31 billion, and animal feed, which rose by $57.4 million. China remained the country's largest supplier, providing $3.92 billion worth of goods, or 29.7% of total imports.On the export front, machinery and transport equipment recorded the largest annual gain, rising by $187.6 million. This was followed by coconut oil and other mineral products, which saw increases of $173 million and $163.6 million, respectively.The US remained the top destination for Philippine exports, taking in $1.30 billion, or 18% of the total. China and Japan followed as the second and third largest export markets, each accounting for a share of about 13%.The widening trade imbalance may add further weight to the Philippines' pre-existing weakness, which is already pressured by the Middle East conflict."Excluding the pandemic period, the pace of increase was the slowest since 2010. Prospects for a meaningful turnaround are also not favorable with household expectations of economic conditions weakening anew," ANZ Chief Economist Sanjay Mathur said.

$^PSEi
Japan's Jobless Rate Falls to Nine-Month Low in April
US Markets

Japan's Jobless Rate Falls to Nine-Month Low in April

Japan's unemployment rate eased to 2.5% in April from 2.7% in March, according to government data released Friday.The latest print was also below market expectations and marked the lowest jobless rate since July 2025.The number of employed people rose to a seasonally adjusted 68.8 million from 68.2 million a month earlier, while the number of unemployed fell to 1.8 million from 1.9 million.The labor market data came as Japan's key inflation gauge showed signs of easing.Core consumer prices, which exclude fresh food, rose 1.4% in April from a year earlier, the slowest pace in four years and below economists' expectations.The softer inflation reading was partly attributed to government measures to ease cost-of-living pressures, including energy subsidies, and could complicate expectations for a near-term Bank of Japan rate hike."This data leaves room for debate whether there is a pressing need for the BOJ to raise rates soon," Taro Saito, head of economic research at NLI Research Institute, was quoted as saying by Bloomberg News."Of course, you can argue that a real rate is too low, so more hikes are justified," he added.Meanwhile, Bank of Japan Governor Kazuo Ueda earlier this week cautioned against drawing simple conclusions from the recent surge in energy prices, saying the inflationary impact would depend on a range of factors beyond oil costs alone."Central banks should not look at oil prices in isolation. The same oil price increase can have very different effects depending on wages, expectations, demand, and exchange rates," Ueda said.Ueda stopped short of signaling the timing of the central bank's next policy move, even as policymakers have become increasingly concerned about higher crude oil prices stemming from tensions in the Middle East and their potential impact on inflation."Looking ahead, higher oil prices will likely ripple through a broad range of items, keeping the Bank of Japan on guard against inflation overshoots. We still expect the BOJ to raise its policy rate to 1% in June," Taro Kimura said, according to Bloomberg.

$^N225
Innovent Biologics Secures Up to $10.5 Billion Pfizer Oncology Deal
US Markets

Innovent Biologics Secures Up to $10.5 Billion Pfizer Oncology Deal

Chinese biopharmaceutical company Innovent Biologics (HKG:1801) has secured an oncology licensing deal with New York-based pharmaceutical giant Pfizer that could potentially be worth up to $10.5 billion.Innovent will receive a $650 million upfront payment and is eligible for up to $9.85 billion in development, regulatory and commercial milestone payments, according to a joint release on Thursday.The company is also entitled to up to "double-digit" royalties on net sales of each approved product.The deal covers 12 early-stage and de novo cancer drug programs from Innovent's pipeline, spanning antibody-drug conjugates (ADCs) with novel payloads and multi-specific antibodies with immune-engaging features, according to the release.Eight of the 12 programs originated by Innovent's early-stage programs, while the remaining four are Pfizer-proposed discovery programs.Under the terms of the deal, Innovent will carry out Phase 1 clinical trials of these programs before Pfizer takes over global development."This agreement brings together best-in-industry expertise of Pfizer and Innovent to advance novel cancer medicines to patients at a global scale," said Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent."By leveraging both companies' complementary resources, we can develop our early-stage oncology pipeline with greater speed and impact to help bring innovative therapies to patients more efficiently worldwide."For Innovent, the agreement further bolsters its presence in the biopharmaceutical market. The company said it has launched 18 products in the market, has five assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage.The company has partnered with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem (KRX:051910) and MD Anderson Cancer Center."This collaboration brings together two highly complementary engines of innovation with a shared ambition to move faster, go further and deliver truly transformative medicines to patients who are waiting," said Jeff Legos, Chief Oncology Officer, Pfizer.The deal with Pfizer is subject to regulatory approvals.The agreement marks Innovent's latest billion-dollar licensing deal with a multinational pharma company after striking a license and collaboration deal with Japan's Takeda Pharmaceutical (TYO:4502) in December 2025.As part of that deal, Innovent licensed two late-stage cancer drug candidates, IBI363 and IBI343, to Takeda, and granted an option over early-stage asset IBI3001. The agreement included an upfront payment of about $1.2 billion.The deal also saw Innovent issuing about 6.9 million new shares to Takeda at HK$112.56 each. The shares represent roughly 0.4% of Innovent's enlarged share capital and generated net proceeds of about HK$777 million.Innovent's shares jumped 6% in early-morning trade in Hong Kong on Friday.

$HKG:1801$KRX:051910$TYO:4502